Semaglutide sleep changes: apnea, fragmentation, fatigue
Semaglutide produces meaningful sleep apnea improvement, with the same first-month fragmentation pattern most GLP-1 patients experience.
The mechanism
Same mechanisms as tirzepatide: weight reduction reduces airway obstruction, improved insulin sensitivity affects breathing control, calorie deficit affects sleep architecture early. Semaglutide doesn't have a dedicated OSA approval (tirzepatide does, via SURMOUNT-OSA), but the mechanism translates.
What to expect
First 4-6 weeks: lighter, more fragmented sleep is common. By week 8: typically resolves. Months 2-6: snoring decreases, apnea symptoms improve in patients with measurable apnea. The magnitude of apnea improvement is somewhat less dramatic than tirzepatide based on the trial data, but still meaningful.
Management
Same approach as tirzepatide. Address the early fragmentation through sleep hygiene; usually self-resolves. For patients with diagnosed OSA on CPAP: don't change settings unilaterally; coordinate with your sleep doctor. Repeat sleep study at 6 months if weight has moved 10%+.
When to escalate
Sleep disturbance past week 8 without improvement. New severe daytime sleepiness with apnea events. Persistent insomnia with mood changes.
- STEP-1 (Wilding et al., NEJM 2021)
- SURMOUNT-OSA (Malhotra et al., NEJM 2024) for the GLP-1 mechanism